HIMS Hims & Hers Health, Inc.
What matters nowUpdated 5 h ago
- The latest development on record is an 8-K filed on Oct 7, 2026, reporting a director or officer change under Item 5.02 1.
- HIMS last traded at $29.99 (pooled 24/7 venue price), down 1.9% from the previous close of $30.58. The largest recent move was +10.15% on Oct 9 (z-score 2.92), followed by -5.07% on Oct 8; the closest filing in our records is the Oct 7 8-K 1.
- Q2 2026 (quarter ended Jun 30, reported Aug 10) revenue was $753.2M, up 38% from a year earlier ·. Trailing twelve-month revenue is $2.58B with a 68.4% gross margin, a -6.0% operating margin and a net loss of $142.0M. Rest of World revenue reached $131.4M in Q2, up from $7.5M a year earlier, helped by the Eucalyptus deal closing in June. Subscribers stood at 2.891 million at the end of Q2, up 19% year over year.
- Market capitalisation is $6.95B, or 2.7 times trailing sales. Over the last 180 days insiders sold 394,683 shares worth $12.0M in 26 sales, all 26 flagged as planned, against one purchase worth $1.2M, a net outflow of $10.8M.
- Next, Q3 2026 earnings are estimated for Nov 9, 2026, not yet confirmed. The September CPI print is due Oct 14 at 12:30 UTC, and Polymarket gives 81.5% odds of no Fed rate change after the October 2026 meeting, against 17.5% for a 25 bp increase.
Valuation & fundamentalsFull financials →
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Every venue
| Venue | Price | vs pool | 24h vol | Open int. | Funding 8h |
|---|---|---|---|---|---|
| binance perp HIMSUSDT · just now | 29.70 | +0.02% | $3.6M | $987.9K | 0.0000% |
| hyperliquid perp xyz:HIMS · just now | 29.67 | −0.10% | $2.1M | $2.4M | -0.0075% |
| okx perp HIMS-USDT-SWAP · just now | 29.69 | −0.02% | $317.7K | $315.6K | 0.0000% |
| bybit perp HIMSUSDT · just now | 29.70 | +0.02% | $63.8K | $262.0K | 0.0000% |
| aster perp HIMSUSDT · just now | 29.74 | +0.15% | $43.3K | $4.7K | 0.0000% |
Pooled price = volume-weighted median of venues within 2% of each other. Venue markets for stocks, indices and gold are 24/7 perpetual contracts; they track but are not the official exchange price.
Open interest, 120 days
US$ millions, all venues
Funding, 120 days
Annualised %, OI-weighted. Positive: longs pay shorts.
NewsAll news →
Hims & Hers names chief medical officers for the UK and Australia
Hims & Hers named Kultar Garcha, MD, as Chief Medical Officer for the UK and EMEA, and Matt Vickers as Chief Medical Officer of Hims Australia.
Hims & Hers shares slide as costly weight-loss push squeezes margins
Hims & Hers shares fell more than 2% in morning trading after second-quarter results, with investors focused on falling gross margins.
Hims & Hers Q2 2026 revenue up 38% to $753 million, but net loss and margin squeeze
Hims & Hers reported second-quarter 2026 revenue of $753.2 million, up 38%, with 2.891 million subscribers.
Hims & Hers completes Eucalyptus acquisition, adding Australia and more customers
Hims & Hers closed its acquisition of Eucalyptus under the terms of the February agreement.
Hims & Hers prices upsized $350 million 0% convertible notes due 2032
Hims & Hers priced an upsized private offering of $350 million of 0% convertible senior notes due June 1, 2032, up from an original $300 million.
Bank of America cuts Hims & Hers target to $30 from $32, keeps Neutral
Bank of America lowered its price target on Hims & Hers to $30 from $32 and kept a Neutral rating.
Hims & Hers Q1 2026 net loss of $92 million; Q2 and full-year guidance set
Hims & Hers reported first-quarter 2026 revenue of $608.1 million, up 4%, and a net loss of $92.1 million, against net income a year earlier.
Hims & Hers nominates Kofi Amoo-Gottfried to its board and shrinks it to nine
Hims & Hers nominated Kofi Amoo-Gottfried, a former chief marketing officer at DoorDash, as a new director for election at its 2026 annual meeting.
Hims & Hers to sell Novo Nordisk's Ozempic and Wegovy and drop compounded GLP-1 ads
Hims & Hers and Novo Nordisk agreed to sell Novo's branded Ozempic and Wegovy, including the Wegovy pill, on the Hims platform.
Hims & Hers guides Q1 2026 revenue below expectations and shares fall
Hims & Hers reported fourth-quarter 2025 revenue of $617.8 million, up 28%, and full-year revenue of $2.35 billion, up 59%.
Hims & Hers agrees to buy Eucalyptus in a deal worth up to $1.15 billion
Hims & Hers signed a definitive agreement to acquire Eucalyptus, an Australian-founded digital health company, for up to $1.15 billion.
Novo Nordisk sues Hims & Hers for patent infringement over compounded semaglutide
Novo Nordisk filed a patent infringement suit against Hims & Hers, alleging that its compounded semaglutide products infringe US Patent 8,129,343.
Hims & Hers drops its compounded copy of Novo's Wegovy pill two days after launch
Hims announced a compounded semaglutide pill on February 5, 2026, priced as a low-cost alternative to Novo Nordisk's Wegovy pill.
Hims & Hers reports fiscal Q3 2025 results: revenue $599.0M, up 49% from a year earlier
Hims & Hers filed a Form 8-K with the SEC on Nov 3, 2025, 4:08 PM ET, reporting an event dated Nov 3, 2025.